The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | Investigating the outcomes and cellular dynamics of cilta-cel versus ide-cel in R/R myeloma
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly comments on the findings of a retrospective international multicenter study that compared idecabtagene vicleucel (ide-cel) to ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory (R/R) multiple myeloma (MM), and investigated the cellular dynamics of treatment with these CAR-T constructs. Dr Gagelmann highlights that information about cellular dynamics holds value, as it can inform individualized clinical decision-making. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yes, so we recently published that as well. We published a study, a retrospective multicenter international study comparing cilta-cel versus ide-cel. And what we showed is that obviously cilta-cel is much, much better, significantly improved PFS with a trend towards improved OS.
But much more importantly, we tried to also evaluate the cellular dynamics and the association with safety and efficacy...
Yes, so we recently published that as well. We published a study, a retrospective multicenter international study comparing cilta-cel versus ide-cel. And what we showed is that obviously cilta-cel is much, much better, significantly improved PFS with a trend towards improved OS.
But much more importantly, we tried to also evaluate the cellular dynamics and the association with safety and efficacy. What we saw is that cilta-cel peaks has a higher expansion at day 14 while ide-cel has that at day 7, so a little bit earlier. But the expansion was associated in both products with response and PFS. But only in cilta-cel the expansion was associated with neurotoxicity, with severe ICANS. So investigating cellular dynamics is very valuable, especially for cilta-cel when it comes to decision making towards individualized therapy, accounting for efficacy and safety.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
